Gilstrap L, Austin AM, Gladders B, et al. - In this population-based, retrospective, cohort study, researchers investigated the relationship between short- (30 day) and long-term (1 year) mortality and the use of neurohormonal therapy among heart failure with reduced ejection fraction (HFrEF) patients, across the age spectrum. A cohort comprising 295,494 fee-for-service beneficiaries with at least one hospitalization for HFrEF between 2008 and 2015, was created using 100% Medicare Parts A and B and a random 40% sample of Part D. This study population had an average age of 80 years, 54% were women and 17% were non-white. Findings showed that at a population level, there was lower short- and long-term mortality, across the age spectrum, in relation to neurohormonal therapy.